The time course of development and impact from viral resistance against ganciclovir in cytomegalovirus infection

C da Cunha-Bang; N Kirkby; Majken Sønderholm; S S Sørensen; H Sengeløv; M Iversen; A Rasmussen; F Gustafsson; Camilla Frederiksen; J Kjaer; A Cozzi Lepri; J D Lundgren

doi:10.1111/ajt.12042

The time course of development and impact from viral resistance against ganciclovir in cytomegalovirus infection

C da Cunha-Bang, N Kirkby, Majken Sønderholm, S S Sørensen, H Sengeløv, M Iversen, A Rasmussen, F Gustafsson, Camilla Frederiksen, J Kjaer, A Cozzi Lepri, J D Lundgren

Afdeling for Klinisk Mikrobiologi

17 Citationer (Scopus)

Abstrakt

(Val)ganciclovir is used to treat cytomegalovirus (CMV) infection following solid organ (SOT) or hematopoietic stem cell (HSCT) transplantation. Treatment failures occur, but the contribution from 39 known ganciclovir-related mutations (GRMs) in the CMV-UL97 gene remains controversial. We propose a categorization of these GRMs potentially useful when interpreting sequence analyses in clinical settings. The UL97 gene was sequenced from first/recurrent CMV infections among consecutive SOT or HSCT recipients during 2004-2009. GRMs were categorized as: Signature GRM (sGRM) if in vitro ganciclovir IC(50) ratio for mutated versus wild-type virus >2 (n = 24); polymorphic GRM (pGRM) if ratio

Originalsprog	Engelsk
Tidsskrift	American Journal of Transplantation
Vol/bind	13
Udgave nummer	2
Sider (fra-til)	458-66
Antal sider	9
ISSN	1600-6135
DOI	https://doi.org/10.1111/ajt.12042
Status	Udgivet - 2013

Adgang til dokumentet

10.1111/ajt.12042

Citationsformater

Cunha-Bang, C. D., Kirkby, N., Sønderholm, M., Sørensen, S. S., Sengeløv, H., Iversen, M., Rasmussen, A., Gustafsson, F., Frederiksen, C., Kjaer, J., Lepri, A. C., & Lundgren, J. D. (2013). The time course of development and impact from viral resistance against ganciclovir in cytomegalovirus infection. American Journal of Transplantation, 13(2), 458-66. https://doi.org/10.1111/ajt.12042

Cunha-Bang, CD , Kirkby, N, Sønderholm, M, Sørensen, SS , Sengeløv, H , Iversen, M, Rasmussen, A, Gustafsson, F, Frederiksen, C, Kjaer, J, Lepri, AC & Lundgren, JD 2013, 'The time course of development and impact from viral resistance against ganciclovir in cytomegalovirus infection', American Journal of Transplantation, bind 13, nr. 2, s. 458-66. https://doi.org/10.1111/ajt.12042

@article{77edc0851fe3460eb905d3873815d776,

title = "The time course of development and impact from viral resistance against ganciclovir in cytomegalovirus infection",

abstract = "(Val)ganciclovir is used to treat cytomegalovirus (CMV) infection following solid organ (SOT) or hematopoietic stem cell (HSCT) transplantation. Treatment failures occur, but the contribution from 39 known ganciclovir-related mutations (GRMs) in the CMV-UL97 gene remains controversial. We propose a categorization of these GRMs potentially useful when interpreting sequence analyses in clinical settings. The UL97 gene was sequenced from first/recurrent CMV infections among consecutive SOT or HSCT recipients during 2004-2009. GRMs were categorized as: Signature GRM (sGRM) if in vitro ganciclovir IC(50) ratio for mutated versus wild-type virus >2 (n = 24); polymorphic GRM (pGRM) if ratio ",

author = "Cunha-Bang, {C da} and N Kirkby and Majken S{\o}nderholm and S{\o}rensen, {S S} and H Sengel{\o}v and M Iversen and A Rasmussen and F Gustafsson and Camilla Frederiksen and J Kjaer and Lepri, {A Cozzi} and Lundgren, {J D}",

year = "2013",

doi = "10.1111/ajt.12042",

language = "English",

volume = "13",

pages = "458--66",

journal = "American Journal of Transplantation",

issn = "1600-6135",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "2",

}

TY - JOUR

T1 - The time course of development and impact from viral resistance against ganciclovir in cytomegalovirus infection

AU - Cunha-Bang, C da

AU - Kirkby, N

AU - Sønderholm, Majken

AU - Sørensen, S S

AU - Sengeløv, H

AU - Iversen, M

AU - Rasmussen, A

AU - Gustafsson, F

AU - Frederiksen, Camilla

AU - Kjaer, J

AU - Lepri, A Cozzi

AU - Lundgren, J D

PY - 2013

Y1 - 2013

N2 - (Val)ganciclovir is used to treat cytomegalovirus (CMV) infection following solid organ (SOT) or hematopoietic stem cell (HSCT) transplantation. Treatment failures occur, but the contribution from 39 known ganciclovir-related mutations (GRMs) in the CMV-UL97 gene remains controversial. We propose a categorization of these GRMs potentially useful when interpreting sequence analyses in clinical settings. The UL97 gene was sequenced from first/recurrent CMV infections among consecutive SOT or HSCT recipients during 2004-2009. GRMs were categorized as: Signature GRM (sGRM) if in vitro ganciclovir IC(50) ratio for mutated versus wild-type virus >2 (n = 24); polymorphic GRM (pGRM) if ratio

AB - (Val)ganciclovir is used to treat cytomegalovirus (CMV) infection following solid organ (SOT) or hematopoietic stem cell (HSCT) transplantation. Treatment failures occur, but the contribution from 39 known ganciclovir-related mutations (GRMs) in the CMV-UL97 gene remains controversial. We propose a categorization of these GRMs potentially useful when interpreting sequence analyses in clinical settings. The UL97 gene was sequenced from first/recurrent CMV infections among consecutive SOT or HSCT recipients during 2004-2009. GRMs were categorized as: Signature GRM (sGRM) if in vitro ganciclovir IC(50) ratio for mutated versus wild-type virus >2 (n = 24); polymorphic GRM (pGRM) if ratio

U2 - 10.1111/ajt.12042

DO - 10.1111/ajt.12042

M3 - Journal article

C2 - 23282281

VL - 13

SP - 458

EP - 466

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 2

ER -

The time course of development and impact from viral resistance against ganciclovir in cytomegalovirus infection

Abstrakt

Adgang til dokumentet

Fingeraftryk

Citationsformater